提供基因检测和辅导的挑战和机遇 粘多糖症II型在肯尼亚提供基因检测和辅导
Lucy N Wainaina Mungai1, Charles Njeru2, Allan Njoroge3
1Department of Paediatrics and Child Health, University of Nairobi, Nairobi, Kenya. dr.lmungai@gmail.com.
Orphanet journal of rare diseases
|November 4, 2025
概括
肯尼亚的II型多糖性粘膜炎 (MPS II) 遗传检测在17个个体中发现了致病变体,显示出女性携带者比例很高. 这项研究可以改善风险家庭MPS II的早期诊断和管理.
科学领域:
- 遗传学 是一个遗传学.
- 生物化学 生物化学
- 儿科 儿科 儿科
背景情况:
- 低收入和中等收入国家有限的遗传资源阻碍了对代谢疾病的诊断.
- 粘多糖症II型 (MPS II) 或亨特综合征是一种遗传疾病,由氨酸-2-硫酶缺乏引起.
- 由于对病因的误解,社会耻辱可能会影响患有遗传疾病的家庭.
研究的目的:
- 评估肯尼亚MPS II的发病率和影响.
- 为疑似MPS II病例提供遗传咨询和检测.
- 在肯尼亚人口中建立MPS II的基因型-表型相关性.
主要方法:
- 提供了遗传咨询和预测咨询.
- 收集了25个人的血液样本,用于酶分析和IDS基因测序.
- 对患有MPS II的男性进行了基因型-表型相关性目录.
主要成果:
- 在25个测试的个体中,在17个个体中发现了致病变体.
- 在这些家庭中发现了18名女性携带者.
- 基因型数据与表型特征,载体率和死亡率相关联.
结论:
- 这项研究展示了肯尼亚MPS II的第一个基因型-表型相关性.
- 调查结果将有助于制定指导方针,用于早期识别处于风险中的个人.
- 可以促进早期评估,特别是对于有MPS II病史的家庭.
更多相关视频
05:58Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format
Published on: August 20, 2018
11.4K
11:54Microsatellite DNA Genotyping and Flow Cytometry Ploidy Analyses of Formalin-fixed Paraffin-embedded Hydatidiform Molar Tissues
Published on: October 20, 2019
9.6K
相关概念视频
What is Genetic Engineering?
70.6K
Overview
70.6K
Cystic Fibrosis: Management
657
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
657
Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
